Category: ACN Newswire

2025年中期业绩亮点- 业务总收益同比增长9.40%至约新台币585.31百万元- 毛利同比增长28.98%至约新台币201.97百万元- 整体毛利率则上升5.24个百分点至约34.51%- 本公司拥有人应占期间全面收益总额同比大幅增长118.02%约至新台币68.24百万元- 统包解决方案的收益约新台币113.69百万元- 每股基本盈利同比增长25.84%至约为新台币4.87仙香港，2025年8月21日 - (亚太商讯 via SeaPRwire.com) - 靖洋集团控股有限公司（「 靖洋集团」或「集团」，股份代号：8257.HK）宣布截至 2025年6月 30 日止六个月（「期内」）之中期业绩。期内，集团业绩呈现稳健增长态势。集团总收益达约新台币585.31百万元，同比增长9.40%。毛利同比增长28.98%，达约新台币201.97百万元，而整体毛利率则上升5.24个百分点至约34.51%。本公司拥有人应占期间全面收益总额约新台币68.24百万元，同比大幅增长118.02%。每股基本盈利约为新台币4.87 仙，同比增长25.84%。期内，统包解决方案的收益约新台币113.69百万元，占集团总收益约19.42%。零件及二手半导体制造设备买卖的收益约新台币471.62百万元，零件及买卖二手半导体制造设备占集团总收益约80.58%。本集团秉持着审慎、稳健的核心策略，致力强化与现有国际客户合作的稳定性和持续性，同时积极拓展新客户以分散风险。期内，本集团源自美国业务的收入较去年大幅增加78.54%，占集团总收益约38.68%，而源自台湾业务的收入则较去年增加48.97%，占集团总收益约49.69%。2025 年上半年，全球半导体市场延续增长态势。在AI 等新技术的驱动下，汽车电子、新能源、物联网、大数据和人工智能等领域的新技术、新产品渗透率持续提升。此外，「人工智能+」、「5G+」等前沿技术的深化发展，以及AI 算力需求的快速增长，均成为推动半导体需求的重要动力，为半导体企业营造了良好的发展环境。根据半导体产业协会最新报告，2025年5月全球半导体销售额达590亿美元，较2024年5月的492亿美元增长19.8%，连续19个月实现同比增长；环比则增长3.5%。全球芯片市场的增长主要受美洲和亚太地区强劲需求推动。靖洋集团主席兼行政总裁杨名翔先生总结：「在AI 技术的强劲驱动下，半导体行业迎来经济利润快速增长期。然而，当前国际形势波动，其亦面临供应链稳定性的挑战。本集团将审时度势，稳中求进，持续提升核心价值与竞争力，为股东创造可持续的长期投资回报。」关于靖洋集团控股有限公司（股份代号：8257.HK）靖洋集团控股有限公司为一间总部位于台湾的零件及二手半导体制造设备的统包解决方案供货商及出口商。集团自于2009年开始业务以来，主要为客户提供零件二手半导体制造设备件的统包解决方案，按客户需要改造及/或升级其生产系统的半导体设备，亦从事半导体制造设备及其零件买卖。集团所提供的半导体制造设备及零件包括热炉管、显影装置等，用于半导体的前端制造过程、晶圆加工，如沉积、光阻涂布及显影，更可广泛应用于手机、游戏机、DVD播放器，以及车用传感器等数码电子产品。本新闻稿由汇滔顾问有限公司代表靖洋集团控股有限公司发布。详情垂询：刘育然小姐电话：(852) 2529 7999电邮：Natural.lau@vitalink.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月21日 - (亚太商讯 via SeaPRwire.com) - 大洋集团控股有限公司 (「大洋集团」或「集团」；股份代号：1991) 作为在港上市近廿载的老牌港股，拟进一步向Web4.0领域及人工智能（AI）产业全面进军，将以AI数字人作为其后续成长引擎，结合真实世界资产（Real World Assets，RWA）代币化运营平台，及其固有的全球流量营销运营体系，针对教育、游戏、大健康三大万亿赛道进行战略布局。在人工智能（AI）为全球数字化卷起新浪潮的大局下，AI正从「技术工具」跃升成为不少企业的「变革核心」，并驱使各行业改变工作方式、突破效率边界、重塑其价值逻辑。IDC研究显示，企业每投资1元在生成式AI身上，其投资回报率可达3.7倍；而深度拥抱AI的企业已实现平均13个月的价值回报周期，超过50%的组织正加速定制化AI应用开发，将短期收益转化为长期竞争优势。普华永道预测，到2030年，AI将成为全球经济的规则改变者，贡献高达 15.7 万亿美元的增长，为中国经济带来约26.1%的 GDP增量。无怪AI数字人作为不同行业多模式交互核心载体，已逐步从概念迈向产业落地。大洋集团于2023年投资的专业数位营销服务公司巨省科技有限公司（「巨省科技」）拟推出其自主研发、技术融合机器学习、自然语言处理（NLP）、计算机视觉（CV）、语音合成／识别（TTS／STT）等领先技术、可兼容xAI Grok API的AI数字人，此AI数字人处于行业领先水平，幷拟面向教育、游戏及大健康的三大场景推出，形成包括但不限于，如能够根据学生专注力实时调整语速及学习难度的「虚拟老师」AI数字人、藉因应每位玩家不同选择互动而衍生「玩家专属」的剧情之AI NPC、可根据个人7x24小时的健康数据如心率、血压等主动建议的「健康伴侣」AI数字人等；集团计划采取「分阶段迭代、逐步开放」的策略，即预期将于未来6个月内完成核心模块及底层技术整合，并目标于紧接的第6至18个月就上述三大场景发布AI数字人原型，幷接入巨省科技之营销矩阵，期望于第18至36个月内能开放相关API或SDK接口，并吸引全球开发者构建其开放式生态圈。除此之外，集团更拟透过是次向AI与数字化转型的契机，计划透过区块链RWA（Real World Assets，真实世界资产），将具备现金流的链下资产项目通过AI数字人实时抓取写进智能合约当中，并将针对教育版权、游戏IP在内等资产进行分层打包及发行，以配合不同投资者的风险偏好，集团目标此类资产发行，首年将对10个优质项目进行「试水式」发行，冀能于未来3年扩展至100个项目，涉及资产规模总值5亿港元；力争5年内服务的资产规模总值能突破50亿港元，打造出多领域RWA资产运营平台。值得留意的是，RWA交易过程中，无需传统经纪商或中间机构的参与，便可实现实体经济与虚拟市场的结合。根据波士顿咨询顾问公司的估计 =，至2030年，RWA代币化市场的市值规模可能成长至16万亿美元。由此可见，其巨大的市场潜力以至前景。依托巨省科技20年跨境投放经验，大洋集团将构建「全域覆盖+智能运营+规模增长」流量体系。巨省科技服务之平台覆盖TikTok、Instagram、Facebook等海外社交平台及抖音、微信视频号等国内渠道，有助客户实现全球用户触达；并可借助AI技术实现账号养号、内容生成、定向投放全流程自动化，降低运营成本，提升获客效率。以此推算，大洋集团对用户增长目标明确：首年引流100万用户构建初始流量池，目标3年内超千万，5年内打造亿级Web4.0原生流量池，形成「流量－转化－复购」的循环。大洋集团将藉上述规划打造「数据化（Digitalization）－资产化（Assetization）－代币化（Tokenization）（下称‧DAT）」闭环，实现价值三层转化：于数据化阶段，将教育教案、游戏脚本等多元数据标准化，打破数据孤岛；在资产化阶段，将用户交互沉淀换算为可量化资产，比如教育「个性化教研数据包」可提升AI数字人老师课程之续费率、游戏「剧情扩展资产」延长游戏生命周期等；在代币化阶段，将可通过滴灌通DRO模型质检之达标资产上链发行，全球投资者可7×24小时交易，放大流动性溢价。针对上述AI及数字化转型战略蓝图的投入规划，大洋集团预期首年投入1.3亿港元，目标未来5年内实现现金流正向循环。大洋集团主席施琦女士表示：「大洋发布助力企业AI与数字化转型蓝图，并正式进入数字资产领域，标志着集团一项重要里程碑，亦为未来更多元化发展掀开崭新的一页。我们感谢各投资者对公司以发展的肯定及信心。大洋集团作为一间在港上市近廿载的老牌港股，透过是次涉足AI产业的举措，未来有望衍生四种收入，包括AI数字人引流的收入、为中小企业提供 AI+RWA 一站式融资咨询的收入、与RWA交易相关的撮合手续费以至数字投顾订阅费、以及按项目或年费提供多语言、多文化 AI 客服与营销外包收入，且巨省科技受惠其业态，近年持续保持正向现金流，亦为是次其向AI及数字转型进一步拓展大计，提供充裕的自有资源，而随着集团透过巨省科技走入AI领域的蓝图逐步变成现实，届时可望为股东创造更多价值幷带来理想回报。」关于大洋集团控股有限公司(股份代号: 1991)大洋集团控股有限公司（股票代号：1991）成立于 1991 年，2007 年在香港联合交易所有限公司成功上市，是一家兼具三十年产业积淀与前瞻数字视野的多元化企业。自创立以来，集团早期聚焦硅胶输入设备领域，专业设计及制造用于消费电子装置、计算机、笔记本电脑、手提电话及汽车周边产品的核心部件，凭借高度整合的生产体系、严苛的品质管控与技术创新能力，赢得全球众多知名品牌客户的长期信赖，奠定了坚实的产业根基。随着全球数字化转型浪潮的深化，大洋集团敏锐洞察数字经济时代的战略机遇，果断启动向 Web4.0 领域的全方位战略转型，以「拥抱技术变革、重构价值生态」为核心方向，精准锚定人工智能（AI）、真实世界资产（RWA）代币化及香港政策生态三大核心驱动力，致力于打通 「数据 — 资产 — 价值」 的转化链路，开启从传统制造向数字经济领航者的跨越。当前，大洋集团正以 Web4.0 战略转型为新起点，聚焦教育、游戏、大健康三大万亿赛道，致力于成为亚太地区 AI 与 RWA 双赛道的领先企业，为全球投资者、合作伙伴及个人用户提供高效的价值增长生态，持续推动全球数字经济高质量发展，写下从「产业深耕者」到「数字生态构建者」的全新一页。如有任何问题，欢迎垂询达博思传讯顾问有限公司陈铠瑶(Joanne Chan)电话：(852) 9616 2676 电邮：jchan@lbs-comm.com何幸儒 (Jason Ho) 电话：(852) 9836 3448 电邮：jho@lbs-comm.com Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. Core product sales and international licensing business progressed in tandem, with multiple ADC pipeline products entering key clinical stages and global commercialization efforts accelerating.Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Lepu Biopharma is dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. The Company is committed to continuously developing a market-differentiating pipeline by fully integrating independent innovation capabilities and strategic collaborations. The Company has established and is progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.Currently, Lepu Biopharma has strategically designed our pipeline with a range of oncology products. For clinical-stage candidates, the Company has one clinical/commercialization-stage drug candidate; nine clinical-stage drug candidates, including one co-developed through a joint venture; and three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody.As of the end of the reporting period, Lepu Biopharma has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and four other products, CMG901, MRG007 and two pre-clinical TCE assets have also been licensed out through our BD activities. Notably, CMG901’s global rights have been licensed to AstraZeneca, and MRG007’s rights for regions outside Greater China have been licensed to ArriVent. Two pre-clinical TCE assets have entered into a collaboration with Excalipoint.Revenue scale achieved a 3.5-fold leapfrog growth, with comprehensive improvement in financial indicatorsIn the first half of 2025, the Company made significant progress in advancing its product pipeline and business operations, recording a total revenue of approximately RMB466 million, which was an increase of 350% of the same period in 2024 at RMB133 million. For licensing activities, the Company has recognized approximately RMB309 million in revenue primarily from the out-licensing of MRG007. The Company recorded a revenue of approximately RMB151 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024. In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services.During the reporting period, the Company achieved profitability for the first time, with a profit of approximately RMB 29.3 million, marking a turnaround from a loss in the same period of 2024. Net cash generated from operating activities was approximately RMB 46.7 million, and cash and cash equivalents increased to approximately RMB 473 million, representing a positive net operating cash flow compared to the same period in 2024. Research and development expenses amounted to approximately RMB 202 million, representing a decrease of 6.6% compared to the same period in 2024. While ensuring the advancement of core pipelines, cost control measures have shown tangible results.The Company actively develops cooperative relationships with various business channel partners. As of June 30, 2025, the Company completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.ADC pipeline enters the critical phase with multiple products, potential for combination therapy highlighted, and fruitful international licensing resultsIn the first half of 2025, the Company remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. In particular, MRG003 for NPC nears approval and other key drug candidates advance to pivotal clinical stage.MRG003（EGFR-ADCNPC: MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as “late breaking abstract (LBA)” for oral presentation at the ASCO Congress 2025. The Company is also currently conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The encouraging data in phase II clinical trial of combination therapy on R/M NPC will be presented at the ESMO Congress 2025.HNSCC: As of June 30, 2025, the Company is conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC. In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and the Company will initiate the clinical trial in the second half of 2025.MRG004A (TF-ADC): The Company has completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, MRG004A was granted BTD by the CDE in August 2025, which offers a brand-new treatment option to patients with pancreatic cancer.MRG006A (GPC3-ADC): MRG006A is a GPC3-targeted ADC with FIC potential globally. We received IND clearance from the FDA in January 2025. We are currently advancing Phase I clinical trial in China. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.MRG007 (CDH17-ADC): We received the IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US$1.2 billion in total in upfront payment and development, regulatory and sales milestones, together with tiered royalties on net sales. As of June 30, 2025, the upfront payment has been received.CG0070 (Oncolytic virus): CG0070 was granted BTD by the CDE in January 2025. CG0070 is currently in a MRCT Phase III clinical study conducted by the Company’s U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. The Company has completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic bridging pivotal linical trial.Combination therapy layout: As of June 30, 2025, the Company has completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. The Company has observed encouraging data on UC. In terms of combination therapy with MRG003 and pucotenlimab, the Company is currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025, which has been moved up to first-line treatment for advanced disease.Preclinical: Laying the groundwork for innovative platforms and innovative targetsThe Company continuously strives to build up and develop novel technology platforms as innovative engines for the Company. The Company has developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPi ADC platform and other early-stage platforms. During the reporting period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, the Company has generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.On August 1, 2025, the Company entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two preclinical assets developed by the Company’s proprietary T cell engager-TOPAbody platform with Excalipoint through entering into the Intellectual Property Assignment and License Agreement.The Company shall receive (i) an upfront payment in cash of US$10 million in aggregate, development and commercial milestone payments in cash of up to US$847.5 million in aggregate and sales royalties, holding a 10% interest, marking international recognition of the platform's value.Future Outlook: Accelerating the Commercialization of Core Products and Advancing Global Strategic DevelopmentIn respect of drug R&D, the Company will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. The Company will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. The Company will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.In terms of domestic commercialization, the Company will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share and enhance the Company's brand image and market recognition. At the same time, the Company will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams.On the international front, the Company will ramp up our efforts to expand into the global market. We will expand our international network and explore new business development cooperation opportunities. The Company will remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China’s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; CanSinoBIO) once again delivered a solid performance.According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, with the reduction exceeding 94% compared to the same period last year. This reflects improved operational quality and lays a solid foundation for steady full-year growth. With core products selling strongly and multiple pipeline programs advancing, CanSinoBIO’s long-term growth story is steadily taking shape.Meningococcal Vaccine Portfolio Continues to Scale, Unlocking Growth DriversCanSinoBIO’s two currently marketed meningococcal conjugate vaccines—the quadrivalent meningococcal conjugate vaccine (MCV4, Menhycia) and the bivalent meningococcal conjugate vaccine (MCV2, Menphecia)—remain the company’s key revenue drivers. In particular, the sustained scaling-up of MCV4 demonstrates strong market competitiveness and is central to CanSinoBIO’s growth narrative.In 2024, Menhycia and Menphecia together generated nearly RMB 800 million in sales revenue, representing year-on-year growth of over 40%. In the first half of 2025, driven by deeper channel penetration and higher terminal market coverage, the sales of both vaccines continued to grow steadily. During the same period, the company’s meningococcal vaccine portfolio generated sales of over RMB 364 million, representing more than 38% year-on-year growth and providing a solid foundation for earnings.As the only MCV4 in China, Menhycia effectively covers four meningococcal serogroups, 'ACYW135', and leverages the high-safety CRM197 carrier protein technology. With outstanding clinical immunogenicity and safety, it has become the preferred choice for many parents seeking meningococcal vaccination for their children.Furthermore, Menhycia’s market potential is still being unlocked. The vaccine has been submitted to the National Medical Products Administration (NMPA) for an expanded age indication—from the current “children aged 3 months to 3 years (47 months)” to “children aged 3 months to 6 years (83 months).” If approved, this will directly broaden its coverage, strengthen penetration in the non-national immunization program market, and inject greater certainty into CanSinoBIO’s growth over the next two to three years, further consolidating the company’s leadership in the meningococcal vaccine field.iPneucia Officially Launched, a New Benchmark for Differentiated Pneumococcal VaccineIn June, CanSinoBIO’s self-developed product — the 13-valent pneumococcal conjugate vaccine (PCV13, iPneucia) — was officially approved for market launch, marking the company’s entry into the RMB 10 billion-plus pneumococcal vaccine market and the beginning of a new growth cycle.Pneumococcal diseases remain a serious global public health concern, with particularly high morbidity and mortality rates among children under five years old. Addressing the remaining immunization gaps in China, the launch of iPneucia fills the domestic technological void in high-end 13-valent pneumococcal conjugate vaccines, demonstrating CanSinoBIO’s leadership in differentiated innovation.Compared with existing competing products in the market, iPneucia achieves breakthroughs in three major dimensions. First, it offers more targeted protection, focusing on four high-risk serotypes—19F, 19A, 7F, and 3 - that together account for over 60% of pneumococcal disease cases among Chinese children. Clinical trial data show that its Geometric Mean Concentration (GMC) of antibodies is significantly higher than that of competing products. Second, in carrier protein technology, it adopts the globally pioneering CRM197+TT dual-carrier technology, overcoming the immune interference limitations of single-carrier vaccines. This both reduces the risk of immune suppression when co-administered with other vaccines and significantly enhances immunogenicity. Finally, in manufacturing safety, iPneucia uses an animal component - free fermentation process, reducing risks associated with animal-derived biological factors. It also employs no formaldehyde detoxification and adds no phenol during production, significantly improving vaccine safety.With these three advantages, iPneucia could potentially become another “ace” for CanSinoBIO in the infant bacterial vaccine market, following Menhycia. Notably, iPneucia shares a highly overlapping target population with Menhycia, creating strong channel synergies that will accelerate commercialization and enable the company to quickly capture market share in the RMB 10 billion-plus pneumococcal vaccine segment.Combination Vaccine Strategy Progresses SteadilyBeyond this, CanSinoBIO’s long-term potential lies in its continued build-out of a “Combination Vaccine” portfolio. Compared with traditional monovalent vaccines, multi-conjugate vaccine and polyvalent vaccine can prevent multiple diseases with a single injection, significantly improving vaccination efficiency and willingness - representing a key global direction in vaccine technology development.Following the quadrivalent vaccine Menhycia and multi-valent vaccine iPneucia, CanSinoBIO’s DTcP-Hib-MCV4 pentavalent vaccine—a representative combination vaccine—has attracted strong market attention. In February this year, it received clinical trial approval, marking a “zero-to-one” breakthrough for the company in the high-end combination vaccine sector.The DTcP-Hib-MCV4 pentavalent vaccine can simultaneously prevent pertussis, diphtheria, tetanus, Haemophilus influenzae type b (Hib) disease, and infection by the four meningococcal serogroups (ACYW135), achieving “protection against five diseases with a single shot”. This significantly reduces the number of injections and improves compliance among infants. More importantly, its core component Menhycia has already undergone commercial validation in China and enjoys a strong reputation, providing robust support for the combination vaccine’s development. This “point-to-surface” product upgrade logic enables CanSinoBIO to advance in the combination vaccine market with greater efficiency and confidence. With the government placing high importance on combination vaccine R&D and offering policy support, CanSinoBIO is well-positioned to capture this high-value market.R&D-Driven Growth with a Clear Product Pipeline and Strong ReservesWhile consolidating its existing market advantages, CanSinoBIO continues to strengthen its mid-to-long-term growth momentum through robust R&D capabilities and differentiated pipeline planning.Its DTcP for infants and young children has entered priority review and is expected to fill a domestic market gap. The Tdcp for people aged 6 years old and above has completed Phase III subject enrollment, enabling full life-cycle immunization coverage. The tetanus vaccine’s registration application has been accepted, and it is expected to offer superior safety and immunogenicity data compared with existing products. The Recombinant Poliomyelitis Vaccine, funded by Gates Foundation, has initiated clinical trials in Indonesia and has also received domestic clinical trial approval. Globally innovative Protein Based Pneumococcal Vaccine (PBPV) and inhaled tuberculosis vaccines have entered clinical research and proof-of-concept validation.The company has now built a rich pipeline covering multiple technology platforms and full life-cycle segments, including meningococcal vaccines, pneumococcal vaccines, diphtheria tetanus pertussis vaccine, polio vaccines, tuberculosis vaccines, and zoster vaccine. Several major products are entering critical stages of registration review or clinical trials. Meanwhile, CanSinoBIO’s continuous breakthroughs in key technology platforms support a strategic shift from reliance on single products to sustained pipeline output.Overall, in the first half of 2025, CanSinoBIO maintained the strong growth momentum seen since 2024, proving that its closed-loop capabilities from product R&D to commercialization have become increasingly mature. Against the backdrop of ongoing national policy support for innovative vaccines and domestic high-end vaccine substitution, CanSinoBIO — leveraging its solid R&D foundation, differentiated pipeline layout, and efficient commercialization execution—is accelerating the realization of its long-term growth potential and moving steadily toward becoming a global leader in innovative vaccines.CanSinoBIO, https://www.cansinotech.com [SSE:688185, HKG:6185, OTC:CASBF] Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. ("Red Cloud"), as sole underwriter and bookrunner, pursuant to which Red Cloud has agreed to purchase for resale 5,555,556 units of the Company (each, a "Unit") at a price of C$0.90 per Unit (the "Offering Price") on a "bought deal" basis in a public offering for gross proceeds of approximately C$5,000,000 (the "Underwritten Offering").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to purchase one common share of the Company (each, a "Warrant Share") at a price of C$1.35 at any time on or before that date which is 36 months after the Closing Date (as herein defined).The Company has granted to the Underwriter an option (the "Over-Allotment Option", and together with the Underwritten Offering, the "Offering"), exercisable, in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale the number of additional Units equal to up to 15% of the number of Units sold pursuant to the Underwritten Offering at the Offering Price to cover over allotments, if any, and for market stabilization purposes.The net proceeds from the Offering will be used by the Company to fund ongoing operations including, but not limited to, commercial development, product development and working capital.In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces and territories of Canada, except Quebec. The Units may also be sold in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and in such other jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction, and provided the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth).Copies of the Shelf Prospectus and the Supplement to be filed in connection with the Offering can be found on SEDAR+ at www.sedarplus.ca. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the Shelf Prospectus and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.The Offering is expected to close on or about September 3rd, 2025 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange to list, on the Closing Date, the common shares of the Company issuable from the sale of Units as well as upon the exercise of the Warrants.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.About GMGGMG is an Australian-based clean-technology company, which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in-house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low-cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy saving coating), which is now being marketed into other applications, including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium ion batteries.GMG's 4 critical business objectives are:Produce Graphene and Improve/Scale Cell Production ProcessesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the expected size and terms of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the Offering; use the proceeds from the Offering as anticipated; the Company's performance and general business and economic conditions.Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the Offering as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the Offering; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263207 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Hengdeli Holdings Limited (“Hengdeli” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 3389) announced its interim results for the six months ended 30 June 2025 ("the period under review"). In the first half of 2025, the global environment remained complex and volatile, with uncertainties such as increasing trade barriers, intensifying trade frictions and continuing geopolitical conflicts weighing on the momentum of global economic growth. Under these pressures, China’s economic growth slowed down but maintained stable amidst multiple domestic and external challenges. Still, the country's economy remained resilient as it carried on with steady and sound development. In the face of a complex and volatile operating environment, the Group has adapted its business to market changes by adhering to the principle of “sound, steady and long-term operations” in order to preserve its market position and pursue new opportunities as well as make every effort to safeguard the interests of its shareholders.During the review period, the Group recorded revenue of RMB314,314,000 (six months ended 30 June 2024: RMB580,361,000), representing a year-on-year decrease of 45.8%; high-end consuming accessories business recorded revenue of RMB248,095,000 (six months ended 30 June 2024: RMB352,339,000), representing a year-on-year decrease of 29.6%; commodity trading revenue amounted to RMB66,219,000 (six months ended 30 June 2024: RMB228,022,000), representing a year-on-year decrease of 71.0%. During the period under review, the Group recorded a profit of RMB26,033,000 (six months ended 30 June 2024: profit of RMB499,000), representing a year-on-year increase of 5,117.0%. Profit attributable to equity shareholders amounted to RMB26,308,000 (six months ended 30 June 2024: loss of RMB2,504,000), representing a year-on-year increase of 1,150.6%. The profit was mainly attributable to foreign exchange gains incurred by the operating units as a result of exchange rate fluctuations.During the period under review, in view of uncertainties in the international market and the slowdown in domestic economic growth, the Group’s high-end consuming accessories business continued to face pressure. The Group has taken various measures to cope with the complicated operating environment, and continued to broaden its business models, acquire new customers and develop new products through innovative approaches. At the same time, the Group has enhanced its technological innovation capabilities, accelerated its mechanization, and standardized and strengthened its information and automation management. All these measures have yielded effective results and improved our ability to cope with risks. During the period under review, the sales performance and profit of the high-end consuming accessories business both recorded year-on-year decreases due to the impact of the operating environment.In terms of international trading, during the period under review, the Group continued to carry out the international commodity trading business in line with its established strategy. The business mainly covers the importation of iron ore, thermal coal and coking coal to Mainland China. Global demand for iron ore grew at a slower pace and prices weakened due to dampening economic prospects as a result of trade frictions. Impacted by fluctuating decline in sales prices of ore sand and weakened customer purchasing intentions, the sales and gross profits of the international commodity trading business decreased as compared to the same period last year but still maintained profitability. The Group planned to establish a bulk cargo transshipment logistics park in Mexico integrating customs clearance, import, transportation and warehousing, and has initiated collaborations with and provided services to multiple large-scale enterprises and listed companies in China. In the second half of the year, the Group will continue to keep abreast of market dynamics, promptly and prudently carry out international commodity trading activities and explore new profit models and future development directions, in order to lay a solid foundation for the Group’s sustainable development.In terms of international shipping, during the period under review, the Group’s international shipping business mainly focused on the global maritime transportation of dry bulk cargo, such as coal, iron ore, manganese ore, bauxite, grain and industrial salt. Our clientele includes internationally renowned mining enterprises and large central state-owned enterprises and listed companies in China. During the period under review, the global dry bulk shipping market was volatile, which affected the freight rates. The Group closely monitored the market conditions, continued to expand its business by developing new customers and signing long voyage transportation contracts with its customers to lock in long-term profits for the Company. In the first half of the year, affected by market fluctuations, both the revenue and profit of the Group’s shipping business recorded a decline.At present, the international political and economic environment is experiencing increased turbulence, with trade barriers and trade frictions worsening. Facing this severe external environment, the economy of Mainland China is also encountering difficulties and challenges, including insufficient demand, sluggish consumption awaiting stimulation, and ongoing structural adjustments. Nevertheless, the economy of Mainland China has a stable foundation, strong resilience and great potential, and the long-term positive development trajectory remains unchanged. With the implementation and refinement of various policies and measures by the Chinese government, we maintain full confidence in the long-term sustainable economic growth of Mainland China.In the second half of the year, the Group will adhere to the principle of “sound, steady, and long-term operations”, and will leverage the stable business environment in Mainland China that “pursues stability while seeking progress” to keep abreast of the market trend and further advance the progress of international trade business prudently and steadily. Additionally, the Group will continuously expand the shipping business, which is closely related to international trade, and strive to become an important participant in the international shipping supply chain, so as to provide support for the breakthroughs in corporate development.The Group will also adapt to changing market demands and continuously enhance its integrated service capabilities in commercial space for both Mainland China and international markets. We will adjust the manufacturing of high-end accessories for renowned watches while promoting a limited number of diversified business activities and expanding high-end consuming accessories manufacturing to other high-end lifestyle products, such as jewellery, eyeglasses, cosmetics, mobile phones and other 3C products. Additionally, we will expand our commercial space beautification services to living space beautification services, thus becoming an indispensable and independent segment in the ecological chain of high-end consuming accessories. Copyright 2025 ACN Newswire via SeaPRwire.com.

Novelty and inventiveness confirmed as Focus Graphite moves closer to securing patent for next-generation lithium-ion battery anode materialsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to provide an update on the status of its patent application entitled "Advanced Anode Materials Comprising Spheroidal Additive-Enhanced Graphite Particles and Process for Making Same" (Canadian patent application No. 3,209,696).The Company reports that no further prior art has been cited in the examination process. The remaining requests for clarification from the examiner are minor in nature, primarily relating to formality issues in the description and figures. Focus is pleased with this outcome and has retained MBM Intellectual Property Law ("MBM") of Ottawa, ON, to prepare and submit claim amendments and expects a positive resolution.In support of its application, Focus has also received the International Preliminary Report on Patentability ("IPRP") issued during the Patent Cooperation Treaty ("PCT"). The IPRP confirmed that the Company's amended claims are both novel and inventive, strengthening the intellectual property protection around Focus' proprietary anode material technology.Additionally, the Company submitted amended claims under the Patent Prosecution Highway ("PPH") for the Canadian case. These amendments, which reduced the number of claims to avoid excess fees, form the basis for the Company's ongoing patent strategy.Dean Hanisch, Chief Executive Officer of Focus Graphite, commented, "This positive progress in our patent application process represents another important milestone in advancing Focus Graphite's downstream strategy. The recognition that our claims are both novel and inventive underscore the uniqueness of our technology and its potential to contribute meaningfully to next-generation lithium-ion battery anode materials."The Company will provide further updates as the application advances.About MBM Intellectual Property LawMBM is an independent, Canadian-owned boutique law firm dedicated exclusively to intellectual property law headquartered in Ottawa. For over 30 years, MBM has provided strategic IP advice and protection for clients ranging from start-ups and universities to multinational corporations. With a diverse team of patent and trademark agents, lawyers, and scientists, MBM manages global patent, trademark, and design portfolios and is recognized for delivering practical, cost-effective solutions. Proudly independent, MBM focuses on building long-term client relationships and maximizing the value of innovation.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated outcome of Focus Graphite's patent application process; the Company's ability to address and resolve the examiner's remaining objections; the expectation of securing patent protection for spheroidal additive-enhanced graphite materials; the potential strategic, commercial, and technological benefits of securing such intellectual property; and the advancement of the Company's downstream strategy to supply advanced graphite materials for lithium-ion batteries in North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263193 Copyright 2025 ACN Newswire via SeaPRwire.com.

FINANCIAL HIGHLIGHTS RMB’000 (Unaudited)6 Months Ended June 303 Months Ended June 302025202420252024 Revenue4,645,407 4,610,641 2,307,412 2,473,766 - Office software and services2,657,122 2,413,079 1,355,653 1,187,730 - Online games and others1,988,285 2,197,562 951,759 1,286,036 Gross Profit3,772,214 3,782,688 1,853,628 2,042,035 Operating Profit984,111 1,395,615 382,658 794,037 Profit Attributable to Owners of Parent816,314 677,923 532,440 393,353 Basic Earnings Per Share (RMB)0.60 0.51 0.39 0.29 HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its unaudited 2025 interim results and its second quarter results for the period ended 30 June 2025.For the first half of 2025, the revenue of Kingsoft increased by 1% year-on-year to RMB 4,645.4 million. Revenue from the office software and services represented 57% and online games and others represented 43% of total revenue. Gross profit reached RMB 3,772.2 million.For the second quarter of 2025, the Company’s revenue reached RMB 2,307.4 million. Revenue from office software and services and online games and others represented 59% and 41%, respectively, of total revenue for the second quarter of 2025. Gross profit for the second quarter of 2025 was RMB 1,853.6 million.Mr. Jun LEI, Chairman of the Company, commented: “In the second quarter, we advanced core businesses steadily in line with established strategy and firmly positioned for the future. Kingsoft Office focused on ‘AI, collaboration, and internationalization’, continued to strengthen the allocation of R&D resources in related fields, and developed solutions deeply aligned with user scenario needs to sustain competitiveness in the field of intelligent office. The online games business continued advancing content innovation and global expansion, achieving the development of flagship IPs and new game genres.”Mr. Tao ZOU, Chief Executive Officer of the Company, added: “The total revenue for the second quarter amounted to RMB 2,307.4 million, representing a year-on-year decrease of 7%, among which the revenue from the office software and services business was RMB 1,355.7 million, representing a year-on-year increase of 14%. Revenue from the online games and others business was RMB 951.8 million, representing a year-on-year decrease of 26%, primarily due to the high base in the same period last year.”BUSINESS REVIEWOffice Software and ServicesFor the first half of 2025, revenue from the office software and services business increased by 10% year-on-year to RMB 2,657.1 million. The increase was mainly attributable to the growth of WPS individual and WPS 365 businesses of Kingsoft Office. Revenue in the second quarter increased by14% year-on-year to RMB 1,355.7 million.In the second quarter, the office software and services business continued its healthy development. For WPS AI, Kingsoft Office released WPS AI 3.0 and launched the native Office intelligent agent ‘WPS Lingxi’ — the core capability module of WPS AI 3.0. WPS AI 3.0 drove deep integration between AI and office software through bidirectional transformation, achieving native embedding of AI capabilities and deep involvement in office workflows. WPS Lingxi integrated multiple AI functions, marking the transition from tool-based AI applications to collaborative intelligent agents. We also implemented intelligent upgrades to WPS 365 components, and launched messaging, meeting, and email assistants to boost office efficiency.For WPS individual business, Kingsoft Office expanded AI benefits and rolled out new AI products. In overseas markets, we initiated the development of the new WPS International Edition to gradually migrate domestic high-value features. For WPS 365 business, we continuously deepened penetration into industries and scenarios, actively promoted the implementation of AI projects, and engaged in co-creation with key clients to replicate and scale up typical solutions. For WPS software business, we actively participated in the bidding for domestic office software of central and local governments and enterprises. Our products maintained a leading share in both flow layout and fixed layout document software market.Online Games and othersFor the first half of 2025, revenue from online games and others business reached RMB 1,988.3 million, and revenue for the second quarter of 2025 was RMB 951.8 million. In the second quarter, the online games business continued to enrich the brand value of classic JX series and expand into new game genres.During the second quarter, JX3 Online, the flagship IP, maintained engaged player base through consistent content updates and technical optimization. The Fate of Sword: Zero was launched, building upon the core gameplay of the classic JX series IP while introducing innovative explorations. The anime shooter game Snowbreak: Containment Zone sustained its long-term operation, keeping stable user base. The self-developed sci-fi mech game Mecha BREAK commenced its global public beta in July. On its launch day, it topped Steam’s lists for both “Most Played” and “Trending Games,” and earned high scores from several international authoritative gaming outlets like IGN.Additionally, we actively strengthened our collaboration with high-quality overseas IPs, deepening the localized operational capabilities in domestic market. The social deduction game Goose Goose Duck obtained the license approval in June and was expected to launch in the second half of the year. The number of pre-registrations exceeded 5 million, demonstrating its popularity. Cats & Soup: Magic Recipe, the sequel to Cats & Soup, secured its license in May. For the latter half of the year, we will focus on refining the operations of our core titles and continuously optimizing the gaming experience based on players’ feedback.Mr. Jun LEI concluded, “In the coming quarters, Kingsoft Office will continue to increase its R&D investments in AI and collaboration, and promote the implementation of its products and services across a wider range of office scenarios in various industries. The online games business will remain focused on premium games, continue to cultivate its IP franchise, steadily advance its global expansion and achieve long-term operations. We believe that these efforts will strengthen the Group’s core competitiveness and lay a solid foundation to achieve long-term high-quality growth.”About Kingsoft Corporation LimitedKingsoft (3888.HK) is a leading Chinese software and internet service company listed on the Hong Kong Stock Exchange. It has three main subsidiaries: Kingsoft Office, Seasun Holdings and Kingsoft Shiyou. With the implementation of the “transformation toward mobile internet” strategy, Kingsoft has completed a comprehensive transformation in its overall business and management model. The Company has established a strategic layout with office software and interactive entertainment as its pillars, and cloud services and artificial intelligence as its new starting points. Kingsoft has more than 8,000 employees worldwide and holds a significant market share domestically. For more details, please refer to http://www.kingsoft.com.Kingsoft Investor Relations:Li YinanTel: +86 10 6292 7777Email: ir@kingsoft.comFor further queries, please contact Hill and Knowlton:Ovina ZhuTel: +852 2894 6315 Email: kingsofthk@hkstrategies.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - To promote Hong Kong’s business advantages and enhance trade and economic cooperation between Hong Kong and Thailand and the wider ASEAN region, Prof Frederick Ma, Chairman of the Hong Kong Trade Development Council (HKTDC), visited Bangkok and met with senior government and business leaders.Prof Ma spoke on a panel at the Singapore Regional Business Forum organised by the Singapore Business Federation. He said, “Businesses are diversifying amid the changing landscape. Asia remains a major engine for economic growth, underpinned by the rise of emerging markets, like ASEAN and the Middle East. China, with its industrial base and vast population, is a stabilising force in an ever-changing world. And Hong Kong, given its superconnector and super value-adder roles, is a dynamic platform linking Mainland China with the world.”Aside from the event, Prof Ma met with Chantawit Tantasith, Deputy Minister of Commerce of Thailand, and Dhanin Chearavanont, Senior Chairman of Charoen Pokphand Group, to exchange views on deepening Hong Kong-Thailand trade and economic cooperation.Prof Ma noted: “Thailand is an important trade and investment partner for Hong Kong. I am delighted that I had the opportunity to exchange insights with the Ministry of Commerce and leading enterprises in Thailand as well as political and business leaders from Singapore to further strengthen the economic ties between Hong Kong and Thailand and the wider ASEAN region.”As a statutory body, the HKTDC promotes, assists and develops Hong Kong’s external trade, while supporting Hong Kong businesses to tap into the opportunities in ASEAN. The HKTDC’s flagship events, such as the Asian Financial Forum and the Belt and Road Summit, serve as ideal platforms to highlight the latest developments and opportunities in Hong Kong as well as the city’s advantages in professional services, while facilitating cross-regional collaboration. Photo Download: http://bit.ly/4lBDJFAHKTDC Chairman Prof Frederick Ma meets with Chantawit Tantasith, Deputy Minister of Commerce of ThailandHKTDC Chairman Prof Frederick Ma meets with Dhanin Chearavanont, Senior Chairman of Charoen Pokphand GroupProf Frederick Ma, Chairman of HKTDC, discusses business resilience in Asia and promotes Hong Kong business advantages at the Singapore Regional Business Forum in BangkokPlease contact the HKTDC’s Communication & Public Affairs Department:Sam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

Results Summary- Total revenue increased by 8% to HK$2,800 million, among which the revenue from Hong Kong increased by 9% to HK$1,600 million while the revenue from Mainland China increased by 9% to HK$700 million – both markets recorded growths- Revenue from the jewellery segment increased markedly by 13% to HK$1,100 million, among which gold products accounted for over 75% of the revenue from the jewellery segment- Gross profit rose by 8% to HK$800 million; gross profit margin remained resilient at 30.1%- Adjusted EBITD1 increased to HK$300 million and net profit rose by 5% to HK$200 million- As at 30 June 2025, bank balances and cash on hand amounted to over HK$1,500 million (31 December 2024: HK$950 million), without any bank borrowings and was in a net cash position, hence its net gearing ratio was zero, indicating a very healthy financial position- Successfully partnered with Mr. Chan Sai Cheong, strives to expand the jewellery business in Mainland China under “Emperor Jewellery”, and has already drawn up a preliminary roadmap for store expansions, with an initial target of 600 stores in Mainland China in the next five years; enables the jewellery business to become its future growth driver under the solid foundation of its watch business- Opened a Patek Philippe flagship store at a prime location in Central, Hong Kong, strengthening its market positionHONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Emperor Watch & Jewellery Limited (“Group” or “Emperor W&J”) (Stock code: 887), a leading retailer of European-made watches and jewellery products, announced its interim results for the six months ended 30 June 2025 (“Period”).In spite of market uncertainties and challenging business environment, the Group’s total revenue grew by 7.6% to HK$2,794 million (2024: HK$2,597 million) during the Period. Revenue from Hong Kong increased by 8.8% to HK$1,594 million (2024: HK$1,465 million), accounting for 57.1% (2024: 56.4%) of the total revenue, and the revenue from Mainland China increased by 8.7% to HK$723 million (2024: HK$665 million), accounting for 25.9% (2024: 25.6%) of the total revenue. In terms of revenue by product segment, the revenue from the watch segment increased by 4.2% to HK$1,700 million (2024: HK$1,632 million), accounting for 60.8% (2024: 62.8%) of the total revenue, and the revenue from the jewellery segment increased markedly by 13.4% to HK$1,094 million (2024: HK$965 million), accounting for 39.2% (2024: 37.2%) of the total revenue, among which gold products accounted for 75.2% (2024: 77.0%) of the revenue from the jewellery segment.The Group’s gross profit increased by 7.7% to HK$840 million (2024: HK$780 million) with gross profit margin remained resilient at 30.1% (2024: 30.0%). The Group’s net profit increased by 4.9% to HK$194 million (2024: HK$185 million) during the Period. Basic earnings per share was HK2.73 cents (2024: HK2.72 cents). The Board declares an interim dividend of HK0.55 cent (2024: HK0.65 cent) per share.As at 30 June 2025, bank balances and cash on hand of the Group amounted to HK$1,508 million (31 December 2024: HK$950 million), without any bank borrowings (31 December 2024: zero) and was in a net cash position, hence its net gearing ratio was zero (31 December 2024: zero), indicating a healthy financial position.During the Period, the Group successfully partnered with Mr. Chan Sai Cheong (“Mr. Chan”), an influential and highly respected jewellery industry veteran with over 40 years of experience, regarding strategic development of the Group’s jewellery business in Mainland China. The Group has drawn up a preliminary roadmap for store expansions in Mainland China, with an initial target of 600 stores in the next five years, opening in phases. During the first phase, the focus will be on opening stores targeting mid-to-high-end market segments in established first-tier and new first-tier cities; this will be followed by an emphasis on stores in second-tier cities, targeting mid-market segment.As at 30 June 2025, the Group had a total of 73 stores in Hong Kong, Macau, Mainland China, Singapore and Malaysia. During the Period, the Group opened two new jewellery stores, in Hong Kong and Macau. Additionally, a Patek Philippe flagship store and a Tudor watch boutique were opened in Hong Kong and Chongqing in Mainland China, respectively. Subsequent to the Period, the Group opened a jewellery store in Hangzhou, Mainland China.Ms. Cindy Yeung, Chairperson of Emperor W&J, said, “With the ongoing pick-up in foot traffic after the resumption of the multiple-entry Individual Visit Scheme for Shenzhen permanent residents, and the tourism blueprint launched by the Hong Kong government, the Group is confident that the overall retail market will further regain its growth momentum. The Patek Philippe flagship store that was recently opened by the Group in Hong Kong will further enhance the Group’s competitive edge in the luxury watch retail market and strengthens its market leading position.”Ms. Yeung concluded, “The Group expects that gold jewellery, as an alternative form of investment, will continue being well received by Chinese consumers, given the volatile property and stock markets. The Group considers the establishment of the strategic partnership with Mr. Chan is a valuable opportunity for expanding its jewellery business in Mainland China. We will effectively expand its retail network footprint with diversified market segmentation strategies, thereby capturing a substantial share of the enormous opportunities in the Mainland China market.”Financial Highlights For the six months ended 30 JuneChanges2024HK$ million2025HK$ millionTotal revenue2,5972,794+ 7.6%Gross profit780840+ 7.7%Gross profit margin30.0%30.1%+ 0.1ppAdjusted EBITD [1]282297+ 5.3%Net profit185194+ 4.9%Basic earnings per shareHK2.72 centsHK2.73 cents+ 0.4%[1] Adjusted EBITD represents earnings before interest, tax and depreciation charge on the self-owned flagship store, which reflects the Group’s core operating performanceAbout Emperor Watch & Jewellery LimitedWith long establishment history of over 80 years in Hong Kong since 1942, Emperor W&J (887.HK) is a leading retailer principally engages in the sale of European-made internationally renowned watches, and jewellery products under its own brand, “Emperor Jewellery”. Through its comprehensive watch dealership, unique marketing campaigns and extensive retail network at prime locations in Hong Kong, Macau, Mainland China, Singapore and Malaysia, Emperor W&J established a strong brand image amongst its target customers ranging from middle to high income groups worldwide. In recognition of its efforts in investor relations communications, Emperor W&J was granted with “Best IR Company” (Small Cap), “Best IR Team” (Small Cap) and “Best Investor Presentation Material” (Small cap) in HKIRA Investor Relations Awards 2025 by the Hong Kong Investor Relations Association. For more information, please visit its website: www.EmperorWatchJewellery.com.Investor/Media EnquiriesAnna LukGroup Investor Relations DirectorTel: +852 2835 6783Email: annaluk@emperorgroup.comJanice AuGroup Investor Relations ManagerTel: +852 2835 6799Email: janiceau@emperorgroup.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Following its highly anticipated global reveal earlier this month, Level Infinite will launch the game's 1st Closed Beta in early November. Players can be the first to get a hands-on with the game this week at gamescom 2025 in Cologne from 20th to 24th August. Rust Mobile delivers a full-scale open-world survival gameplay that millions of fans know and love, optimized for mobile devices.Officially licensed by Facepunch Studios, Rust Mobile stays true to the spirit of the original while introducing a fresh way to survive on the go. From gathering resources and building fortified bases to ruthless PvP combat and the tension of trust and betrayal, the mobile version captures the essence of Rust. Players will have the opportunity to experience all the excitement the game offers firsthand at both gamescom and through the upcoming Closed Beta Test.Rust Mobile at Gamescom 2025Attendees can find the Rust Mobile booth in Hall 06.1 - C-051G, where they'll get hands-on time with the game and take part in activities designed to bring the world of Rust to life. Activities include interacting with themed props, immersing themselves in the booth environment.Every participant will also earn a spin on the Loot Wheel, with the chance to win exclusive Gamescom 2025 memorabilia, including limited-edition posters and tote bags.1st Closed Beta Coming This NovemberRust Mobile's 1st Closed Beta will launch in early November 2025, inviting 30,000 players from North America, Western Europe, and select regions in Asia.The beta will feature four language options English, Japanese, Traditional Chinese, and Thai and will support iOS, Android, and tablet devices, ensuring players can experience the game on their platform of choice.Registration for the Closed Beta Test is now open at www.rustmobile.comFor more information about Rust Mobile or to pre-register, head to rustmobile.com, or follow the game on X, and YouTube. For gamescom opening times visit www.gamescom.global.About Level InfiniteLevel Infinite is Tencent's global games brand, dedicated to delivering engaging and original gaming experiences to a worldwide audience, whenever and wherever they choose to play. The brand also provides a wide range of services and resources to a network of developers and partner studios around the world to help them unlock the potential of their games. Level Infinite is both publisher of breakout hit games like PUBG MOBILE, Honor of Kings and Goddess of Victory: NIKKE and a collaborative partner in games such as Dune: Awakening from Funcom, Warhammer 40K: Darktide and many more. To learn more about Level Infinite, visit www.levelinfinite.comContact InformationKirsty EndfieldSwipe Right PRtencent@swiperight.ggSOURCE: Level Infinite Copyright 2025 ACN Newswire via SeaPRwire.com.

业绩摘要- 本期间的总收入上升8%至28亿港元，其中来自香港的收入上升9%至16亿港元，而来自中国内地的收入上升9%至7亿港元，两地均录得增长- 珠宝分部的收入显著上升13%至11亿港元，当中黄金产品占珠宝分部的收入超过7成半- 毛利增加8%至8亿港元；毛利率为30.1%，表现呈抗跌力- 经调整EBITD1上升至3亿港元，净利润增加5%至2亿港元- 于2025年6月30日，银行结余及手头现金为超过15亿港元(2024年12月31日：9.5亿港元)，没有任何银行借贷，并处于净现金状况，因此净负债比率为零，反映财务状况非常健康- 成功伙拍陈世昌先生，致力扩展「英皇珠宝」于中国内地之珠宝业务，并已拟定初步开店路线图，初期目标是于未来五年分阶段于中国内地开设600间店铺。在其具韧性的钟表业务基础上，务求珠宝业务成为未来增长动力- 于香港中环黄金地段开设了一间百达翡丽旗舰店，进一步巩固市场地位香港，2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 欧洲制钟表及珠宝首饰之零售商翘楚－英皇钟表珠宝有限公司(「本集团」或「英皇钟表珠宝」)(股份编号：887)公布其截至2025年6月30日止六个月(「本期间」)之中期业绩。纵使市场存在不明朗因素及营商环境充满挑战，本集团于本期间的总收入增加7.6%至27.9亿港元(2024年：26.0亿港元)。来自香港的收入增加8.8%至15.9亿港元(2024年：14.7亿港元)，占总收入57.1%(2024年：56.4%)，而来自中国内地的收入增加8.7%至7.2亿港元(2024年：6.7亿港元)，占总收入25.9% (2024年：25.6%)。按产品分部划分的收入而言，钟表分部的收入上升4.2%至17.0亿港元(2024年：16.3亿港元)，占总收入60.8% (2024年：62.8%)，而珠宝分部的收入显著增加13.4%至10.9亿港元(2024年：9.7亿港元)，占总收入39.2% (2024年：37.2%)，当中黄金产品占珠宝分部的收入约75.2% (2024年：77.0%)。本集团的毛利增加7.7%至8.4亿港元(2024年：7.8亿港元)，毛利率为30.1% (2024年：30.0%)，表现呈抗跌力。本集团于本期间的净利润增加4.9%至1.94亿港元(2024年：1.85亿港元)。每股基本盈利为2.73港仙(2024年：2.72 港仙)。董事会宣派中期股息每股0.55港仙(2024年：0.65 港仙)。于2025年6月30日，本集团之银行结余及手头现金为15.1亿港元(2024年12月31日：9.5亿港元)，没有任何银行借贷(2024年12月31日：零)并处于净现金状况，因此净负债比率为零(2024年12月31日：零)，显示健康的财务状况。于本期间，本集团就其于中国内地珠宝业务之策略性发展成功伙拍陈世昌先生（「陈先生」）。陈先生为一位于珠宝行业具影响力且备受推崇的资深人士，拥有超过40年的经验。本集团已初步拟定于中国内地扩展店铺的路线图，初期目标是于未来五年分阶段开设600 间店铺。于第一阶段，开店的重点会落在成熟的一线城市及新一线城市，面向中高端市场；后续开店将侧重于二线城市，面向中端市场。于2025年6月30日，本集团于香港、澳门、中国内地、新加坡及马来西亚营运共73间店铺。于本期间，本集团于香港及澳门新开设两间珠宝店，另外亦分别于香港及中国内地重庆开设一间百达翡丽旗舰店及一间帝舵表钟表专卖店。本期间后，本集团于中国杭州开设一间珠宝店。英皇钟表珠宝主席杨諾思女士表示︰「随着深圳户籍居民一签多行个人游计划恢复后人流持续回升，加上香港政府推行的旅游业蓝图，本集团有信心整体零售市场将进一步重拾增长动力。本集团近期于香港开业的百达翡丽旗舰店，将进一步提升本集团于名贵钟表零售市场的竞争优势，并巩固其市场领先地位。」杨女士总结道︰「鉴于物业及股票市场波动，本集团预期作为另类投资的黄金珠宝将继续受中国消费者欢迎。本集团认为与陈先生建立战略合作伙伴关系，将为扩展其于中国内地之珠宝业务带来宝贵机会。我们将以多元化市场细分策略，有效地扩大其零售网络布局，从而在中国内地市场的庞大商机中抢占重大份额。」财务亮点 截至6月30日止六个月变动2024年百万港元2025年百万港元总收入2,5972,794+ 7.6%毛利780840+ 7.7%毛利率30.0%30.1%+ 0.1百份点经调整EBITD[1]282297+ 5.3%净利润185194+ 4.9%每股基本盈利2.72港仙2.73港仙+ 0.4%[1]经调整EBITD为利息、税项及自家拥有旗舰店的折旧费用前之盈利，以反映本集团之核心营运表现关于英皇钟表珠宝有限公司作为零售商翘楚，英皇钟表珠宝(887.HK)自1942年在香港开业至今已有超过80年悠久历史，业务包括销售享誉国际之欧洲制腕表及旗下「英皇珠宝」品牌之珠宝首饰。凭借其代理齐全的钟表品牌、独特的市场推广策略以及遍布香港、澳门、中国内地、新加坡及马来西亚黄金地段的广泛零售网络，英皇钟表珠宝在全球各地中高收入人士的目标顾客群中已建立稳固的品牌形象。于香港投资者关系协会颁发的2025年香港投资者关系大奖中，英皇钟表珠宝荣获「最佳投资者关系公司-小型股」、「最佳投资者关系团队-小型股」及「最佳投资者关系素材-小型股」。有关详细资料，请浏览其网站︰www.EmperorWatchJewellery.com。投资者/媒体查询陆文静集团投资者关系总监电话︰+852 2835 6783电邮：annaluk@emperorgroup.com区雪莹集团投资者关系经理电话电话︰+852 2835 6799电邮：janiceau@emperorgroup.com Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月21日 - (亚太商讯 via SeaPRwire.com) - 比优集团控股有限公司（「比优集团」或「本公司」，连同其附属公司统称「本集团」，股份代号：09893.HK）欣然宣布，近日集团获国内领先金融数据平台Wind提升ESG评级，由BB级跃升至A级，跻身行业前列，充分体现集团在可持续发展方面的卓越表现。Wind ESG评级A级代表企业在环境、社会及管治维度的综合实力处于行业头部领先水平。据Wind最新评级结果显示，在基础化工行业中，获得A级的企业仅占约19.35%，显示出比优集团在ESG管理及实践方面已居于行业上游。本集团ESG评级实现从BB至A的两级跨越，主要得益于系统性的可持续发展举措。根据比优集团最新发布的《2024/2025年度环境、社会及管治报告》，集团在环境层面全面落实大气污染物减排、温室气体管控、废弃物资源化及生态修复等项目，大力推进绿色矿山建设与社会责任履行；在社会维度，持续完善安全生产体系与员工健康保障，强化产品质量与供应链合规管理，特别是在"一带一路"沿线国家推行本地化运营，积极践行社区共建与企业公民责任；在管治维度，集团建立了系统、全面的合规管理制度和风险控制流程，通过常态化的审计监察与员工培训，严守商业道德底线，积极预防舞弊与腐败行为，并设立了对董事会直接负责的ESG工作组，将可持续发展深度融入公司治理核心。Wind作为中国金融信息服务业最具权威性与影响力的平台之一，其ESG评级体系依托强大的数据治理能力与深厚的行业积累，构建了涵盖大量定量与定性指标的科学评估框架。该体系接轨国际标准，深度融合中国本土信息披露政策与企业实践，Wind ESG评级结果与底层数据已全面覆盖A股、港股上市公司，公募信用债发债主体及国内公募基金。本次比优集团ESG评级的上调，反映了其在治理结构优化、环境与社会绩效提升、以及信息披露质量方面获得第三方评级机构的高度认可。董事会相信，此次评级的跃升不仅体现了集团在可持续发展方面的扎实进展，也将进一步强化投资者的信心。未来，比优集团将继续深化绿色运营、推进技术革新，持续提升ESG管理的透明度，积极践行可持续发展理念，推动实现高质量的企业成长。关于比优集团控股有限公司比优集团控股有限公司（主板股票代号：09893.HK）是一家专注于民用爆炸品的生产销售、爆破工程服务，矿山资源开发和勘探业务的领军企业。集团在国内市场占据重要份额，并在中亚等全球市场积极拓展业务。公司网址：http://www.pizugroup.com Copyright 2025 亚太商讯 via SeaPRwire.com.

深圳, 2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 在本月早些时候备受期待的全球首秀之后，Level Infinite 将于11月初开启《Rust Mobile》首次封闭测试。玩家们可以在 2025 年 8 月 20 日至 24 日于科隆举办的 gamescom 上，率先亲身体验这款游戏。《Rust Mobile》将经典的开放世界生存玩法完整呈现，并针对移动设备进行了优化，让数百万粉丝熟悉并热爱的体验随时随地都能上手。本作由 Facepunch Studios 官方授权，在忠实还原原作精神的同时，也为移动端带来全新的生存方式。从收集资源、建造坚固基地，到残酷的 PvP 战斗，以及伴随信任与背叛而来的紧张氛围，移动版完整呈现了《Rust》的核心精髓。玩家不仅能够在 gamescom 上率先感受游戏的魅力，还可通过即将到来的封闭测试进一步体验其独特乐趣。《Rust Mobile》亮相 2025 科隆游戏展参展观众可前往 06.1 展馆 - C-051G 展位，在这里亲身体验游戏，并参与一系列将《Rust》世界带入现实的特色活动。活动包括与主题道具互动、沉浸式感受展位环境等。每位参与者都将获得一次转动“战利品转盘”的机会，有机会赢取 2025 科隆游戏展独家纪念品，包括限量版海报和环保袋。首次封闭测试将于今年11月开启《Rust Mobile》首次封闭测试将于 2025 年 11 月初上线，届时将邀请来自北美、西欧及部分亚洲地区的 30,000 名玩家参与。本次测试将提供四种语言版本：英语、日语、繁体中文和泰语，并支持 iOS、Android 及平板设备，确保玩家能够在自己熟悉的平台上畅玩游戏。封闭测试现已开放注册，玩家可前往 www.rustmobile.com 报名。欲了解更多有关《Rust Mobile》的信息或进行预注册，请访问 rustmobile.com，或关注游戏的 X 账号与 YouTube 频道。有关科隆游戏展开馆时间，请访问 www.gamescom.global。关于 Level InfiniteLevel Infinite 是腾讯旗下的全球游戏品牌，致力于随时随地为全球玩家带来引人入胜且独具特色的游戏体验。该品牌还为全球范围内的开发者和合作工作室提供多种服务与资源，帮助他们释放游戏潜力。Level Infinite 既是《PUBG MOBILE》《王者荣耀》《胜利女神：NIKKE》等爆款游戏的发行商，也是《沙丘：觉醒》（Funcom 开发）、《战锤40K：Darktide》等众多游戏的深度合作伙伴。欲了解更多关于 Level Infinite 的信息，请访问 www.levelinfinite.com 。联系信息Kirsty EndfieldSwipe Right PRtencent@swiperight.gg来源: Level Infinite Copyright 2025 亚太商讯 via SeaPRwire.com.

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.

- 朗豪坊商场开业20周年"立足本地，引领全球潮流文化"，成品牌进驻热点，Chiikawa拉面首间海外分店掀热潮- 花园道三号于2025年到期的租约已全部处理，续约率维持在高水平- 朗豪坊办公楼推出结合六大健康维度"6D Wellness"的创新概念，强化其一站式身心健康及生活时尚总汇的市场定位- 香港银行同业拆息下降节省利息开支，2025年债务成功全额再融资香港，2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 持有花园道三号及朗豪坊物业的冠君产业信托（股份代号：2778）公布截至 2025 年 6 月 30 日止的中期业绩。业绩摘要 2025上半年2024上半年变动租金收益总额 （百万港元）1,0291,115- 7.6%物业收益净额（百万港元）859954- 10.0%可分派收入（百万港元）476544- 12.6% 每基金单位分派（港元）0.07010.0809- 13.3% 于2025年6月30日于2024年12月31日变动物业组合总值（百万港元）58,09860,104- 3.3%每基金单位资产净值（港元）6.797.16- 5.2%资产负债比率24.5%23.7%+ 0.8pp概览2025年上半年，尽管全球经济因贸易紧张局势和地缘政治冲突而面对重重阻力，但香港的市场气氛获多项利好因素支持。股市回暖、香港银行同业拆息于第二季回落，住宅销售趋稳定，以及旅游业稳步复苏均有助抗衡外部压力。然而，港人外游热潮未退，消费力外移令本地零售市道受压。与此同时，写字楼租赁市场依然淡静，反映供求持续失衡。在此市况下，本信托的可分派收入下跌12.6%至4.76亿港元，而每基金单位分派（"每基金单位分派"）则减少13.3%至0.0701港元。冠君产业信托行政总裁侯迅女士（左），冠君产业信托投资及投资者关系总监陆嘉萍女士（右）花园道三号虽然中环整体写字楼市场的租赁动力仍然疲弱，但随着金融市场转趋活跃，我们接到的租赁查询有所增加，需求主要来自金融相关企业。花园道三号落实引进一批新的租赁面积较小的租户，包括家族办公室；而一名现有银行业租户亦于物业内扩充。于2025年6月30日，花园道三号写字楼的出租率为80.7%。该物业的租金收益期内减少5.4%至5.40亿港元（2024年：5.71亿港元）。我们持续推动续租工作，2025年到期的租约已全部处理完毕且续约率维持在高水平，当中包括多名主要租户的续租。而2026年到期的租约亦有超过70%已续租。朗豪坊办公楼报告期内，朗豪坊办公楼推出名为"6D Wellness"的YouTube频道，藉此强化朗豪坊办公楼作为一站式身心健康及生活时尚总汇的市场定位。于2025年6月30日，在该物业的租户组合中，生活时尚（身心健康）行业租户占比达68%。于2025年6月30日，朗豪坊办公楼的出租率保持在86.9%的稳定水平。我们扩大了共享工作空间的营运规模并增设"Social Wellness Hall"，专为举办工作坊及交流活动而设，正好呼应办公楼推广身心健康的定位。市场租金继续面对挑战，租金收益因而减少9.1%至1.51亿港元（2024年：1.66亿港元）。冠君产业信托行政总裁侯迅女士朗豪坊商场今年迎接开业20周年的朗豪坊商场，继续秉持"Stay Local，Trend Global"（"立足本地，引领全球潮流文化"）的愿景。透过沉浸式体验和限定商品，我们成功吸引破纪录的人潮及推动销售，并在八月刷新单日人流纪录。近日，首次进军香港的时装品牌BENLAI，以及全城首家以生活风格为主题的期间限定店Umbro均在朗豪坊商场开业，人气拉面店Chiikawa Ramen Buta亦选址朗豪坊商场设立首家海外分店，旋即成为高人气新热点。于2025年6月30日，商场的出租率维持在99.2%的高水平，目前属已承诺悉数租出的状态。消费行为的改变为租户带来挑战，租金收益跌至3.38亿港元（2024年：3.78亿港元）。分派本信托期内可分派收入下跌12.6% 至4.76亿港元（2024年：5.44亿港元），而每基金单位分派则减少13.3%至0.0701港元（2024年：0.0809港元）。按2025年6月30日的基金单位收市价2.08港元计算，相当于年度分派率6.7%。资产值于2025年6月30 日，本信托旗下物业组合的估值为581亿港元，较2024年12月31日的601亿港元减少3.3%。可持续发展我们继续透过提升气候抗御力、建立有意义的联系及促进社区福祉，为我们的生态圈创造共享价值。报告期内，花园道三号引入人工智能制冷机组优化系统，全年节省大厦制冷设备的能源用量达6.1%。我们透过"绿'惜'环保约章"计划，推动写字楼和零售租户携手实现可量化的环保目标。此外，我们举办以"创新．启发．融合"为主题的"冠君产业信托 ESG Gala"，凝聚逾千名租户和商业伙伴，共同推进可持续营运及共融举措。展望尽管香港零售业已重拾增长，金融市场亦见反弹，预料本信托于2025年后续期间的整体经营环境依然严峻。虽然港元利率回落有助节省利息支出，但续租租金下跌或将持续压抑租金收益及令分派较去年为低。面对竞争激烈的市场环境，我们将继续以灵活的营运策略积极应对。有关冠君产业信托(股份代号：2778)冠君产业信托拥有及投资提供租金收入的写字楼及零售物业。信托主要投资位于优越地点的甲级商用物业。现时拥有花园道三号及朗豪坊两幢位于香港的地标性物业，并以合资股权形式拥有位于伦敦市中心的 66 Shoe Lane，总楼面面积约300万平方呎，让投资者可直接投资于优质甲级写字楼及零售物业。信托自2023年荣获全球房地产GRESB可持续的最高五星级别。冠君产业信托管理人乃鹰君资产管理（冠君）有限公司，为鹰君集团的成员。网站: www.championreit.com Copyright 2025 亚太商讯 via SeaPRwire.com.

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com.

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.